STEMI slide kits
ST-elevation myocardial infarction (STEMI): The basics
The rate of ST segment elevation myocardial infarction (STEMI) is declining in high-income countries whereas an upward trend is observed in developing countries. The slide kit covers the STEMI basics including detailed data on epidemiology, with trends across different populations, countries, ages and gender. Costs associated with acute myocardial infarction (AMI), global burden prediction for 2030, as well as EU forecast 2020 for healthcare costs are included. The pathophysiology section offers insight into risk factors (modifiable and non-modifiable), necrosis in MI, acute coronary syndrome and thrombus formation. A section on symptoms and diagnosis describes the STEMI types defined by ECG changes, diagnostic criteria and the typical symptoms of acute myocardial infarction (AMI).
STEMI treatment: Role of fibrinolysis
A comprehensive slide kit highlighting the importance of improving time to treatment in STEMI, the strategies as well as guidelines needed for STEMI management. Several key factors on organisation and future improvements required in successfully sustaining STEMI networks are mentioned. Thrombolytic agents are reported and information about Metalyse® (tenecteplase) is also included. Important clinical outcomes and conclusions of studies such as the ASSENT trial series, FINESSE and DANAMI-2 are discussed. Key data from several registries (Vienna STEMI, Minneapolis STEMI & the French registries) are highlighted.
Pharmaco-invasive strategy in ST-elevation myocardial infarction (STEMI)
The slide kit descibes STEMI pharmaco-invasive strategy, it’s importance as well as guidelines approved by international STEMI experts. Key details from several clinical studies (e.g. WEST, GRACIA-2, TRANSFER-AMI, NORDISTEMI, CAPTIM, STEPP-AMI, STREAM, EARLY-MYO) are reported. In addition, STEMI data from well-known registries is included with a summary of take home points.